Introduction
============

Cervical cancer (CESC) is one of the leading etiologies of malignant tumor deaths in woman aged 20--39 years. According to the National Center for Health Statistics, in 2017, there were 12,820 estimated new cases of CESC and 4,210 estimated deaths caused by CESC in America.[@b1-cmar-10-6489] In fact, CESC deaths in developing countries account for 90% of the world's total death toll, causing severe public health problems and financial burden.[@b2-cmar-10-6489] Some studies have shown that miRNAs are associated with the development and prognosis of CESC.[@b3-cmar-10-6489]--[@b5-cmar-10-6489] Previous studies have reported that lymph node metastasis (LNM) in early-stage CESC influences the patient's survival and outcomes of subsequent adjuvant therapy, but there is limited research on the relationship between LNM and miRNAs in early-stage CESC.[@b6-cmar-10-6489]--[@b9-cmar-10-6489] Therefore, it is meaningful to study the molecular mechanisms of CESC and identify miRNA markers for individualized treatment plans and prognostic prediction of CESC. miRNAs are small noncoding RNAs of \~22 nucleotides in length that play regulatory roles in RNA silencing.[@b10-cmar-10-6489]

miRNAs are involved in regulating 30% of human genes.[@b11-cmar-10-6489] Through the regulation of target genes, miRNAs play a role in cell cycle regulation, cell proliferation, apoptosis, drug resistance, and other biological processes (BPs).[@b12-cmar-10-6489]--[@b17-cmar-10-6489] Additionally, miRNAs are stable in tissue, blood, and urine.[@b18-cmar-10-6489]--[@b20-cmar-10-6489] Therefore, miRNAs show promise for use in the diagnosis and treatment of CESC.

The Cancer Genome Atlas (TCGA) contains genomic and proteomic data from more than 20 tumor types, with the benefits of a large sample size, a unified testing platform, and complete follow-up information; moreover, an increasing number of studies utilize data from this database.[@b3-cmar-10-6489],[@b5-cmar-10-6489],[@b21-cmar-10-6489]--[@b23-cmar-10-6489] High-throughput dataset analysis may provide a useful method for the identification of hub genes and patterns in CESC. In this study, we analyzed the differences in miRNA expression patterns between early-stage CESC patients with LNM \[LNM(+)\] and without LNM \[LNM(−)\]. Additionally, we analyzed the prognostic value of these miRNAs (hsa-miR-508, hsa-miR-509-2, and hsa-miR-526b) and their possible mechanisms of action, which may offer new insight for improving CESC treatment and patient survival. Based on our results, hsa-miR-508, hsa-miR-509-2, and hsa-miR-526b may be potential diagnostic biomarkers and prognostic indicators of CESC.

Materials and methods
=====================

CESC patients in TCGA
---------------------

The information and miRNA data for 307 patients with CESC were obtained from the TCGA database (<https://cancergenome.nih.gov/>). The exclusion criteria were as follows: 1) information on LNM was not provided or not applicable; 2) the clinical stage was not stage IA2--IIA (International Federation of Gynecology and Obstetrics 2009 criteria); and 3) the clinical data were incomplete. A total of 145 patients with early-stage CESC in the training group were used to analyze differentially expressed genes (DEGs). In addition, 275 CESC patients in the validation group were used to evaluate the prognosis of CESC.

miRNA expression data analyses
------------------------------

The miRNA expression analyses were performed using the "edgeR" package in R.[@b24-cmar-10-6489] From a total of 1,046 miRNAs, 422 miRNAs were detected in at least two cohorts, and miRNAs with no ID on miRBase21 or with a mean expression \<3 raw counts were removed. Each individual miRNA was log2-transformed for further analysis. All DEGs were considered significant if the absolute fold changes were more than 1.5 and the *P*-value was \<0.05.

Prediction of miRNA target genes
--------------------------------

To date, miRWalk2.0 is the only comprehensive archive that can be accessed for free, providing the largest available predictive and experimental miRNA--target interaction data and offering novel and unique features.[@b25-cmar-10-6489] Target genes of three miRNAs were predicted based on the miRWalk database, and overlapped genes among the miRanda, PITA, and Targetscan databases were selected. A *P*-value\<0.05 represented statistical significance.

GO, KEGG, and PPI network analyses
----------------------------------

Gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses are the common methods for studying the functions and pathways associated with large-scale genome data or transcriptional data. GO and KEGG enrichment analyses were performed using BiNGO 3.0.3 and DAVID 6.8.[@b26-cmar-10-6489],[@b27-cmar-10-6489] The protein--protein interaction (PPI) networks were analyzed through the STRING 10.5 database and Molecular Complex Detection (MCODE) 1.5.1.[@b28-cmar-10-6489],[@b29-cmar-10-6489] The network was further visualized using Cytoscape 3.6.1.[@b30-cmar-10-6489]

Statistical analyses
--------------------

The data are shown as the mean ± SD or as the median. Chi-square tests were used to assess differences in race, tumor grade, and tumor status between the LNM(+) and LNM(−) cohorts. Other data, such as age and smoking history, were evaluated using independent-sample *t*-tests. Kaplan--Meier survival analyses and univariate and multivariate Cox proportional risk regression analyses were conducted to compare miRNA levels (high- and low-expression levels) and prognosis.

The data were analyzed using GraphPad Prism 5.0 (La Jolla, CA, USA) and R software, and a *P*-value \<0.05 was considered statistically significant.

Results
=======

The effect of lymph node status on the survival of CESC patients
----------------------------------------------------------------

This study involved 145 patients with early-stage CESC, including 32 LNM(+) patients and 113 LNM(−) patients. The clinical data of these patients are presented in [Table 1](#t1-cmar-10-6489){ref-type="table"}. Indeed, there were no significant differences in age, race, smoking history, or tumor grade between the LNM(+) and LNM(−) patients. Survival analysis showed that the survival time of the LNM(+) group was shorter than that of the LNM(−) group (*P*\<0.05; [Figure 1](#f1-cmar-10-6489){ref-type="fig"}).

Differentially expressed miRNAs in LNM(+) and LNM(−) patients
-------------------------------------------------------------

Comprehensive miRNA profiles of early-stage CESC were generated for LNM(+) and LNM(−) patients. In total, 75 miR-NAs were differentially regulated and had a *P*-value \<0.05 and an absolute fold change of more than 1.5 ([Supplementary table S1](#SD1-cmar-10-6489){ref-type="supplementary-material"}). As shown in [Figure 2](#f2-cmar-10-6489){ref-type="fig"}, of these 75 miRNAs, 24 miRNAs (32.0%) were downregulated in LNM(+) patients, while the remaining 51 (68.0%) miRNAs were upregulated in LNM(+) patients. Seventy-five miRNAs were selected for further analyses.

Identification of miRNAs correlated with the survival of CESC patients
----------------------------------------------------------------------

To identify the association between miRNAs and the survival of CESC patients, the overall survival times of 275 CESC patients in the TCGA dataset were analyzed by the Kaplan--Meier method and log-rank tests. The results showed that patients with high hsa-miR-508 or hsa-miR-526b levels had a longer overall survival time than did those with low hsa-miR-508 level or hsa-miR-526b levels (log-rank test: *P*=0.006, 0.003), as shown in [Figure 3](#f3-cmar-10-6489){ref-type="fig"}. The correlation of hsa-miR-509-2 level with overall survival time in the 275 CESC patients was not significant. The miRNA expression data are shown in [Figure 4](#f4-cmar-10-6489){ref-type="fig"} and [Table 2](#t2-cmar-10-6489){ref-type="table"}.

Univariate and multivariate Cox regression analyses in CESC patients
--------------------------------------------------------------------

The clinical features of age, smoking history, clinical stage, tumor grade, and metastasis were considered in the univariate and multivariate Cox regression analyses to analyze the prognosis of CESC patients. The univariate analysis suggested that there was a significant association between overall survival time and clinical stage (HR: 2.329, 95% CI: 1.423--3.812, *P*=0.001), hsa-miR-508 (HR: 0.511, 95% CI: 0.315--0.828, *P*=0.006), and hsa-miR-526b (HR: 0.484, 95% CI: 0.294--0.795, *P*=0.004). No significant association was observed between overall survival time and age, smoking history, tumor grade, or metastasis. The multivariate analysis suggested that clinical stage (HR: 2.368, 95% CI: 1.414--3.967, *P*=0.001), hsa-miR-508 (HR: 0.496, 95% CI: 0.298--0.826, *P*=0.007), hsa-miR-509-2 (HR: 0.596, 95% CI: 0.363--0.980, *P*=0.041), and hsa-miR-526b (HR: 0.591, 95% CI: 0.350--0.996, *P*=0.048) were prognostic factors for CESC ([Table 3](#t3-cmar-10-6489){ref-type="table"}).

Functional implication of prognostic miRNA signatures
-----------------------------------------------------

To further analyze the mechanisms of these miRNAs (hsa-miR-508, hsa-miR-509-2, and hsa-miR-526b) in CESC, we used miRWalk2.0, which identifies overlapping genes between miRanda, PITA, and the Targetscan databases to predict target genes. Then, we performed functional enrichment analysis with GO and KEGG using BiNGO and DAVID. The GO BP terms were remarkably enriched in epithelial cell development, regulation of cell shape, neuronal migration, and so on. For the GO cellular component (CC) terms, the target genes were concentrated in the cortical actin cytoskeleton, postsynaptic density, and so on. The molecular function (MF) category was focused on steroid hormone receptor activity, NOTCH binding, and so on ([Figure 5](#f5-cmar-10-6489){ref-type="fig"}, [Table 4](#t4-cmar-10-6489){ref-type="table"}). In addition, the KEGG pathways were mostly enriched in cancer pathways, including the MAPK, cAMP, PI3K/Akt, mTOR, and estrogen signaling pathways ([Figure 6](#f6-cmar-10-6489){ref-type="fig"}, [Table 5](#t5-cmar-10-6489){ref-type="table"}). The GO network was illustrated as an interaction network using the Cytoscape plug-in BiNGO, which maps the main functional categories of a given gene set in the GO hierarchy. As shown in [Figure 7](#f7-cmar-10-6489){ref-type="fig"}, the regulation of cellular and primary metabolic processes was important in the BP network. In the CC network, the cell and intracellular components were in core positions ([Figure 8](#f8-cmar-10-6489){ref-type="fig"}). Additionally, the ion, cation, metal ion, and zinc ion binding components were significant in the MF network ([Figure 9](#f9-cmar-10-6489){ref-type="fig"}).

Selection of hub proteins
-------------------------

The PPI network of target genes was analyzed according to the STRING database, including 956 nodes and 3,448 edges. Then, we used the MCODE plug-in in Cytoscape software to build the core module, which consist of 29 nodes and 95 edges (MCODE score: 7.000). The highly connected node with the highest height is considered the hub protein of the network. A total of 29 proteins were selected as the most significant hub proteins, including TP53 (a target of hsa-miR-508, hsa-miR-509-2, and hsa-miR-526b), MMP1 (a target of hsa-miR-509-2 and hsa-miR-526b), NOTCH1 (a target of hsa-miR-509-2), SMAD4 (a target of hsa-miR-508 and hsa-miR-526b), and NFKB1 (a target of hsa-miR-508), which might be associated with LNM in early-stage CESC ([Figure 10](#f10-cmar-10-6489){ref-type="fig"}).

Discussion
==========

CESC is one of the major primary gynecological tumors that affect women's health. In developing countries, the 5-year overall survival rate is only 46%, which is far lower than that of developed countries.[@b2-cmar-10-6489] LNM in the early stage affects the prognosis of CESC.[@b6-cmar-10-6489] Therefore, it is necessary to identify prognostic miRNAs and determine their molecular mechanisms. In this study, we found that hsa-miR-508, hsa-miR-509-2, and hsa-miR-526b were downregulated in LNM(+) patients and could effectively evaluate the prognosis of CESC. Moreover, we explained the potential mechanisms via GO and KEGG enrichment and PPI network analyses of target genes.

As far as we know, there is limited research on the role of these three miRNAs (hsa-miR-508, hsa-miR-509-2, and hsa-miR-526b) in CESC. We first demonstrated that three miRNAs were downregulated in early-stage CESC LNM(+) patients and influenced the prognosis of CESC through bio-informatics analysis. In a recent study, Liu et al reported that hsa-miR-508 is an independent, protective prognostic factor of glioma, and functional tests confirmed that overexpression of hsa-miR-508 inhibits the migration of glioma cells, which was similar to the results of our study.[@b31-cmar-10-6489] In gastric cancer, hsa-miR-508 inhibits the invasion of gastric cancer cells by targeting S-phase kinase-associated protein 2.[@b32-cmar-10-6489] Huang et al also found that hsa-miR-508 expression is downregulated in gastric carcinogenesis cell lines and plays a major role as a tumor suppressor gene in gastric cancer.[@b33-cmar-10-6489] Moreover, miRNA microarray profiling showed that hsa-miR-508 expression is downregulated in lymph node metastatic tissues.[@b34-cmar-10-6489] In addition, Zhai et al indicated that hsa-miR-508 inhibits renal cell cancer cell invasion and migration.[@b35-cmar-10-6489] hsa-miR-509 serves as a cancer suppressor gene in various cancers, such as lung cancer, breast cancer, renal cell cancer, and pancreatic cancer.[@b36-cmar-10-6489]--[@b40-cmar-10-6489] hsa-miR-509 can inhibit tumor cell invasion and migration through target genes. Using bioinformatics analysis, hsa-miR-509 was found to be downregulated in breast cancer and brain metastasis compared to primary cancer and was shown to play a role in suppressing brain metastasis by regulating the RhoC-TNF-α network in both in vivo and in vitro experiments.[@b41-cmar-10-6489] Additionally, low expression levels of hsa-miR-509 were associated with poor outcomes in pancreatic cancer patients.[@b39-cmar-10-6489] hsa-miR-526b can inhibit tumor progression by targeting MMP1.[@b42-cmar-10-6489] Meanwhile, Zhang et al found that hsa-miR-526b is downregulated in lung cancer, and low expression was associated with poor clinical outcomes through the p53/p21 pathway.[@b43-cmar-10-6489] In colon cancer, hsa-miR-526b was reported to be downregulated in metastatic tissue and to inhibit cell proliferation and invasion by regulating the hub gene HIF-1α.[@b44-cmar-10-6489] Liu et al observed that low hsa-miR-526b expression correlates with poor prognosis in hepatocellular carcinoma and enhanced lung metastasis in mouse lungs via the ERK pathway.[@b45-cmar-10-6489]

To investigate the mechanism of LNM in early-stage CESC, we conducted KEGG pathway and GO annotation enrichment analyses and PPI network analyses on three miRNA target genes. Pathway enrichment analysis showed that the target genes were mainly enriched in pathways in cancer, such as MAPK, cAMP, PI3K/Akt, and mTOR pathways. The MAPK pathway has been reported to play a role in the tumor progression of CESC.[@b13-cmar-10-6489],[@b46-cmar-10-6489],[@b47-cmar-10-6489] Zhang et al found that the MAPK pathway was associated with LNM in head and neck cancer.[@b48-cmar-10-6489] Research has shown that the Akt/ mTOR pathway is activated in medullary thyroid carcinoma with lymph node metastases.[@b49-cmar-10-6489] In the coexpression regulatory network of target genes, multiple studies have shown that a TP53 gene mutation increases the risk of CESC.[@b50-cmar-10-6489]--[@b52-cmar-10-6489] MMP1 has been associated with LNM in esophageal squamous cell cancer,[@b53-cmar-10-6489] lung cancer,[@b54-cmar-10-6489] and gastric cancer.[@b55-cmar-10-6489] Liu et al reported that MMP1 promotes esophageal squamous cell carcinoma cell migration and invasion via the PI3K/ Akt pathway.[@b53-cmar-10-6489] In CESC, NOTCH1 has been associated with LNM, and high expression of NOTCH1 indicates a poor prognosis in patients.[@b56-cmar-10-6489] At the same time, Park et al found that NOTCH1 could be a molecular marker of LNM in papillary thyroid cancer.[@b57-cmar-10-6489] In pancreatic and colorectal cancer, SMAD4 was found to be associated with LNM and survival.[@b58-cmar-10-6489],[@b59-cmar-10-6489] Another gene in the network, NFKB1, was reported to increase the risk of LNM in gastric cancer and oral cancer.[@b60-cmar-10-6489],[@b61-cmar-10-6489] These results suggest that the target genes of these three miRNAs play a significant role in LNM in early-stage CESC.

However, there are some deficiencies in our research at present. Although the three miRNAs were downregulated in LNM(+) patients according to the bioinformatics analyses, the original samples need additional validation. Functional tests need to be conducted, and the mechanism of LNM in early-stage CESC needs further study. Our group is currently pursuing some of these research goals.

Conclusion
==========

Using bioinformatics analysis, we have shown for the first time that three miRNAs were downregulated in early-stage CESC LNM(+) patients and are potential prognostic indicators for CESC. In addition, five central genes (TP53, MMP1, NOTCH1, SMAD4, and NFKB1) were found to be directly or indirectly involved in LNM in early-stage CESC. Taken together, the results of the present study suggest that hsa-miR-508, hsa-miR-509-2, and hsa-miR-526b may be potential new diagnostic and prognostic markers for CESC in the future.

Supplementary material
======================

###### 

Differentially expressed microRNAs in LNM(+) and LNM(−) patients

  No.   ID               log2(FC)   *P*-value   FDR         Regulation in LNM(+)
  ----- ---------------- ---------- ----------- ----------- ----------------------
  1     hsa-mir-599      −5.611     2.83E--05   8.53E--04   Down
  2     hsa-mir-499      −4.191     4.60E--06   3.08E--04   Down
  3     hsa-mir-767      −2.967     1.43E--03   1.62E--02   Down
  4     hsa-mir-551b     −2.847     5.13E--06   3.08E--04   Down
  5     hsa-mir-105-2    −2.463     1.38E--02   8.09E--02   Down
  6     hsa-mir-105-1    −2.453     1.09E--02   6.66E--02   Down
  7     hsa-mir-885      −2.388     3.05E--04   4.59E--03   Down
  8     hsa-mir-891a     −1.962     1.06E--02   6.54E--02   Down
  9     hsa-mir-449a     −1.897     4.71E--03   4.16E--02   Down
  10    hsa-mir-520a     −1.869     5.67E--03   4.87E--02   Down
  11    hsa-mir-509-1    −1.801     4.55E--04   6.18E--03   Down
  12    hsa-mir-506      −1.798     1.23E--02   7.42E--02   Down
  13    hsa-mir-509-2    −1.741     1.47E--03   1.62E--02   Down
  14    hsa-mir-509-3    −1.697     1.08E--03   1.34E--02   Down
  15    hsa-mir-526b     −1.666     8.89E--03   5.89E--02   Down
  16    hsa-mir-508      −1.569     2.92E--04   4.56E--03   Down
  17    hsa-mir-514-3    −1.526     3.19E--03   2.99E--02   Down
  18    hsa-mir-514-2    −1.358     8.12E--03   5.78E--02   Down
  19    hsa-mir-514-1    −1.331     9.10E--03   5.89E--02   Down
  20    hsa-mir-1248     −0.902     1.60E--02   9.13E--02   Down
  21    hsa-mir-181b-2   −0.811     8.98E--03   5.89E--02   Down
  22    hsa-mir-3651     −0.721     4.59E--02   2.33E--01   Down
  23    hsa-mir-582      −0.714     4.90E--02   2.34E--01   Down
  24    hsa-mir-425      −0.694     1.43E--03   1.62E--02   Down
  25    hsa-mir-548v     0.615      4.64E--02   2.33E--01   Up
  26    hsa-mir-3677     0.628      9.46E--03   6.03E--02   Up
  27    hsa-mir-1228     0.632      6.25E--03   5.06E--02   Up
  28    hsa-mir-889      0.633      1.57E--02   9.03E--02   Up
  29    hsa-mir-379      0.635      8.37E--03   5.78E--02   Up
  30    hsa-mir-1274b    0.635      3.30E--02   1.78E--01   Up
  31    hsa-mir-2277     0.644      8.34E--03   5.78E--02   Up
  32    hsa-mir-337      0.666      8.26E--03   5.78E--02   Up
  33    hsa-mir-299      0.714      6.80E--03   5.30E--02   Up
  34    hsa-mir-382      0.735      5.90E--03   4.87E--02   Up
  35    hsa-mir-138-2    0.751      3.35E--02   1.78E--01   Up
  36    hsa-mir-409      0.761      2.11E--03   2.12E--02   Up
  37    hsa-mir-411      0.794      1.95E--03   2.00E--02   Up
  38    hsa-mir-127      0.815      4.16E--04   5.84E--03   Up
  39    hsa-mir-543      0.877      1.02E--02   6.39E--02   Up
  40    hsa-mir-654      0.881      1.89E--03   1.99E--02   Up
  41    hsa-mir-3127     0.897      2.43E--05   8.52E--04   Up
  42    hsa-mir-539      0.917      1.43E--03   1.62E--02   Up
  43    hsa-mir-149      0.919      2.61E--04   4.39E--03   Up
  44    hsa-mir-412      0.920      1.58E--03   1.71E--02   Up
  45    hsa-mir-487a     0.920      7.78E--03   5.78E--02   Up
  46    hsa-mir-129-1    0.927      7.72E--03   5.78E--02   Up
  47    hsa-mir-129-2    0.940      3.19E--03   2.99E--02   Up
  48    hsa-mir-487b     0.946      4.82E--04   6.35E--03   Up
  49    hsa-mir-1266     0.956      8.46E--04   1.08E--02   Up
  50    hsa-mir-494      0.980      2.67E--03   2.61E--02   Up
  51    hsa-mir-758      1.016      3.54E--04   5.13E--03   Up
  52    hsa-mir-615      1.020      4.74E--03   4.16E--02   Up
  53    hsa-mir-154      1.029      1.55E--04   2.71E--03   Up
  54    hsa-mir-369      1.036      5.57E--05   1.17E--03   Up
  55    hsa-mir-548b     1.070      2.92E--04   4.56E--03   Up
  56    hsa-mir-655      1.071      1.33E--04   2.55E--03   Up
  57    hsa-mir-370      1.088      1.52E--04   2.71E--03   Up
  58    hsa-mir-376c     1.141      2.82E--05   8.53E--04   Up
  59    hsa-mir-493      1.164      3.47E--05   8.63E--04   Up
  60    hsa-mir-134      1.167      1.26E--05   5.81E--04   Up
  61    hsa-mir-377      1.180      3.48E--05   8.63E--04   Up
  62    hsa-mir-410      1.183      3.11E--05   8.63E--04   Up
  63    hsa-mir-495      1.221      6.34E--06   3.33E--04   Up
  64    hsa-mir-137      1.245      8.76E--03   5.89E--02   Up
  65    hsa-mir-432      1.250      5.50E--05   1.17E--03   Up
  66    hsa-mir-937      1.256      1.38E--05   5.81E--04   Up
  67    hsa-mir-219-2    1.262      7.88E--03   5.78E--02   Up
  68    hsa-mir-485      1.278      4.86E--05   1.14E--03   Up
  69    hsa-mir-433      1.336      1.07E--04   2.14E--03   Up
  70    hsa-mir-376a-1   1.432      2.34E--05   8.52E--04   Up
  71    hsa-mir-376b     1.552      4.70E--07   4.94E--05   Up
  72    hsa-mir-380      1.691      2.57E--06   2.17E--04   Up
  73    hsa-mir-431      1.739      2.74E--08   3.85E--06   Up
  74    hsa-mir-323      2.175      5.30E--09   2.23E--06   Up
  75    hsa-mir-376a-2   2.222      1.26E--08   2.64E--06   Up

**Abbreviations:** ID, miRNA ID; FC, fold change; FDR, false discovery rate.
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![Survival analysis of early-stage LNM(+) and LNM(−) cervical cancer patients.\
**Note:** Kaplan--Meier survival curves show that LNM(+) was associated with poor prognosis in early-stage CESC patients.\
**Abbreviations:** CESC, cervical cancer; LNM, lymph node metastasis.](cmar-10-6489Fig1){#f1-cmar-10-6489}

![Differentially expressed miRNAs in LNM(+) patients.\
**Notes:** Volcano plots of miRNAs were constructed using fold changes and *P-*values. The vertical lines correspond to a 1.5-fold change in expression (up or down), and the horizontal line represents *P=*0.05. The green points on the plot represent the 24 differentially expressed miRNAs that were downregulated in LNM(+) patients, and the red points on the plot represent the 51 differentially expressed miRNAs upregulated in LNM(+) patients.\
**Abbreviation:** LNM, lymph node metastasis.](cmar-10-6489Fig2){#f2-cmar-10-6489}

![Kaplan--Meier survival curves of the expression of the three miRNAs of interest in CESC.\
**Notes:** Kaplan--Meier survival curves show that low miRNA expression was associated with poor survival in CESC patients. Patients were divided into high and low levels according to the median of each miRNA. (**A**) hsa-miR-508; (**B**) hsa-miR-509-2; (**C**) hsa-miR-526b.\
**Abbreviation:** CESC, cervical cancer.](cmar-10-6489Fig3){#f3-cmar-10-6489}

![Differential expression of the three miRNAs of interest in LNM(+) and LNM(−) patients.\
**Notes:** (**A**) The expression levels of hsa-miR-508 in LNM(+) and LNM(−) patients. (**B**) The expression levels of hsa-miR-509-2 in LNM(+) and LNM(−) patients. (**C**) The expression levels of hsa-miR-526b in LNM(+) and LNM(−) patients. The expression level values were calculated using log2-transformed values.\
**Abbreviation:** LNM, lymph node metastasis.](cmar-10-6489Fig4){#f4-cmar-10-6489}

![GO terms for the target genes of three miRNAs using DAVID.\
**Abbreviation:** GO, gene ontology.](cmar-10-6489Fig5){#f5-cmar-10-6489}

![KEGG pathways for the target genes of three miRNAs using DAVID.\
**Abbreviations:** HCM, hypertrophic cardiomyopathy; KEGG, Kyoto Encyclopedia of Genes and Genomes.](cmar-10-6489Fig6){#f6-cmar-10-6489}

![The BP network showed as an interaction network using the Cytoscape plug-in BiNGO.\
**Notes:** Color depth represented the degree of enrichment of GO terms. The significance of enrichment is represented by yellow color (*P*\<0.05).\
**Abbreviations:** BP, biological process; GO, gene ontology.](cmar-10-6489Fig7){#f7-cmar-10-6489}

![The CC network showed as an interaction network using the Cytoscape plug-in BiNGO.\
**Notes:** Color depth represented the degree of enrichment of GO terms. The significance of enrichment is represented by yellow color (*P*\<0.05).\
**Abbreviations:** CC, cellular component; GO, gene ontology.](cmar-10-6489Fig8){#f8-cmar-10-6489}

![The MF network showed as an interaction network using the Cytoscape plug-in BiNGO.\
**Notes:** Color depth represented the degree of enrichment of GO terms. The significance of enrichment is represented by yellow color (*P*\<0.05).\
**Abbreviations:** GO, gene ontology; MF, molecular function.](cmar-10-6489Fig9){#f9-cmar-10-6489}

![PPI network of hub proteins.\
**Notes:** The MCODE was conducted to screen modules of the PPI network with a degree cutoff =2, node score cutoff =0.2, *k*-core =2, and maximum depth =100.\
**Abbreviation:** PPI, protein--protein interaction.](cmar-10-6489Fig10){#f10-cmar-10-6489}

###### 

Clinical characteristics of patients with early-stage CESC

  Category                                     Cohort LNM+ (n=32)   Cohort LNM− (n=113)   *P*-value
  -------------------------------------------- -------------------- --------------------- -----------
  Age (years)                                                                             0.580
   Mean ± SD                                   47.13±13.14          46.04±12.89           
   Median                                      46                   45                    
  Race                                                                                    0.122
   Asian                                       2                    10                    
   White                                       21                   86                    
   Black or African American                   7                    7                     
   Native Hawaiian or other Pacific islander   0                    1                     
   American Indian or Alaska native            0                    2                     
  Smoking history                                                                         0.422
   Mean ± SD                                   1.75±1.29            1.54±1.22             
   Median                                      2                    1                     
  Tumor grade                                                                             0.911
   G1 + G2                                     17                   61                    
   G3 + G4                                     14                   48                    
   GX                                          0                    3                     
   NA                                          1                    1                     
  Tumor status                                                                            0.001
   With tumor                                  11                   12                    
   Tumor free                                  18                   88                    
   NA                                          0                    4                     
   Unknown                                     3                    9                     

**Abbreviations:** CESC, cervical cancer; LNM, lymph node metastasis; NA, not available.

###### 

Three downregulated miRNAs in early-stage CESC patients with lymph node metastases

  No.   ID              log2(FC)   *P*-value     FDR           Regulation
  ----- --------------- ---------- ------------- ------------- ------------
  1     hsa-mir-508     −1.57      2.92×10^−4^   4.56×10^−3^   Down
  2     hsa-mir-509-2   −1.74      1.47×10^−3^   1.62×10^−2^   Down
  3     hsa-mir-526b    −1.67      8.89×10^−3^   5.89×10^−2^   Down

**Abbreviations:** FC, fold change; FDR, false discovery rate ID, miRNA identification.

###### 

Univariate and multivariate Cox regression analyses in CESC patients

  Category                                   Univariable HR (95% CI)   *P*-value   Multivariable HR (95% CI)   *P*-value
  ------------------------------------------ ------------------------- ----------- --------------------------- -----------
  Age (\>60 years vs \<60 years)             1.688 (0.994--2.799)      0.053                                   
  Smoking history (\>3 years vs \<3 years)   0.582 (0.276--1.226)      0.154                                   
  Clinical stage (III + IV vs I + II)        2.329 (1.423--3.812)      0.001       2.368 (1.414--3.967)        0.001
  Tumor grade (G3 + G4 vs G1 + G2)           0.798 (0.482--1.320)      0.379                                   
  Metastasis (M1 vs M0)                      2.450 (0.889--6.749)      0.083                                   
  hsa-miR-508 (high vs low)                  0.511 (0.315--0.828)      0.006       0.496 (0.298--0.826)        0.007
  hsa-miR-509-2 (high vs low)                0.655 (0.409--1.050)      0.079       0.596 (0.363--0.980)        0.041
  hsa-miR-526b (high vs low)                 0.484 (0.294--0.795)      0.004       0.591 (0.350--0.996)        0.048

**Abbreviation:** CESC, cervical cancer.

###### 

GO terms enriched in target genes

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO ID        GO term                                                                                           Count   *P*-value     Genes                                                                      miRNA
  ------------ ------------------------------------------------------------------------------------------------- ------- ------------- -------------------------------------------------------------------------- ----------------
  BP                                                                                                                                                                                                              

  GO:0002064   Epithelial cell development                                                                       8       1.52×10^−5^   *B4GALT1, SHROOM3, HYDIN, ONECUT1, SLC9A4, ONECUT2, TP63, SLC4A5*          hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0008360   Regulation of cell shape                                                                          28      2.42×10^−4^   *GNA13, DMTN, SHROOM3, WASF3, HEXB, FERMT2, ATP10A, RHOQ,* etc             hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0001764   Neuron migration                                                                                  22      6.93×10^−4^   *DCC, TUBB2B, SOX1, NDN, ASTN1, FZD3, SPOCK1, NTN1,* etc                   hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0008654   Phospholipid biosynthetic process                                                                 12      8.80×10^−4^   *PPARD, AGPAT5, LPGAT1, SH3GLB1, SERAC1, HEXB, MBOAT2, PISD,* etc          hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0030335   Positive regulation of cell migration                                                             31      2.05×10^−3^   *CGA, ONECUT1, WASH1, ONECUT2, LRRC15, SEMA5A, ITGAV, SEMA3F,* etc         hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0043401   Steroid hormone- mediated signaling pathway                                                       14      2.06×10^−3^   *PPARD, THRB, ESRRB, RXRA, PAQR8, RORB, NR2C2, NR1H2,* etc                 hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0030522   Intracellular receptor signaling pathway                                                          11      2.15×10^−3^   *NOTCH2, PPARD, NCOA2, THRB, NR1D2, ESRRB, RORB, NR2F2,* etc               hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0007010   Cytoskeleton organization                                                                         27      4.47×10^−3^   *DMTN, TUBB2B, WASF3, ABLIM3, NEDD9, RHOU, DMD, STRIP2,* etc               hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  CC                                                                                                                                                                                                              

  GO:0030864   Cortical actin cytoskeleton                                                                       12      1.46×10^−3^   *EEF1A1, PPP1R9A, SHROOM2, NF2, MED28, SHROOM4, LASP1, FLOT2,* etc         hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0014069   Postsynaptic density                                                                              31      1.57×10^−3^   *NETO2, DMTN, LZTS1, SYNDIG1, CNN3, CPEB3, BMPR2, SPOCK1,* etc             hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0055038   Recycling endosome membrane                                                                       12      1.79×10^−3^   *SCAMP1, RAP2B, RAB11FIP4, RAP2A, RAB11FIP2, RAP2C, WASH1, SLC26A7,* etc   hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0000932   Cytoplasmic mRNA processing body                                                                  17      1.83×10^−3^   *NANOS2, CNOT2, BTBD6, APOBEC3H, CNOT7, APOBEC3F, CAPRIN1, PATL1,* etc     hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0043235   Receptor complex                                                                                  23      2.93×10^−3^   *EGFR, RNMT, IL23R, OLR1, LDLR, RXRA, TGFBR1, LIFR, SMAD3,* etc            hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0000139   Golgi membrane                                                                                    75      4.42×10^−3^   *SLC9A8, OSBP, SEC24A, NDST1, VAPB, FAM20B, CNGB1, RHOU,* etc              hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0031901   Early endosome membrane                                                                           21      4.68×10^−3^   *EGFR, MMGT1, SYNDIG1, WASH1, PML, EEA1, CFTR, WLS,* etc                   hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0005884   Actin filament                                                                                    14      5.93×10^−3^   *MYO5A, DMTN, MYO1B, RHOQ, ACKR2, ACTN2, MYO9B, GNG12,* etc                hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0015629   Actin cytoskeleton                                                                                33      5.99×10^−3^   *MTSS1, DMTN, CNN3, SHROOM4, ONECUT2, KNTC1, PDLIM2, ARHGAP35,* etc        hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  MF                                                                                                                                                                                                              

  GO:0003707   Steroid hormone receptor activity                                                                 14      1.82×10^−3^   *PPARD, THRB, ESRRB, RXRA, PAQR8, RORB, NR2C2, NR1H2,* etc                 hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0005254   Chloride channel activity                                                                         13      3.95×10^−3^   *GABRG1, SLC1A4, GABRG2, GABRG3, GABRA4, CLIC4, SLC26A7, CLIC5,* etc       hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0005112   Notch binding                                                                                     7       4.85×10^−3^   *NOV, NOTCH1, HIF1AN, DNER, AAK1, JAG1, GALNT11*                           hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0003779   Actin binding                                                                                     41      4.86×10^−3^   *MYO5A, LRRC10, DMTN, SHROOM2, CNN3, WASH1, WASF3, IMPACT,* etc            hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0004879   RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding   10      5.30×10^−3^   *NR1H2, PPARD, NR1D2, ESRRB, RXRA, RORB, NR2F2, NR1H4,* etc                hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b

  GO:0000980   RNA polymerase II distal enhancer sequence-specific DNA binding                                   14      7.12×10--3    *CDX2, ESRRB, NFKB1, MBD2, GZF1, NONO, ARX, FLI1,* etc                     hsa-miR-508\
                                                                                                                                                                                                                  hsa-miR-509-2\
                                                                                                                                                                                                                  hsa-miR-526b
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BP, biological process; CC, cellular component; GO, gene ontology; MF, molecular function.

###### 

KEGG pathways enriched in target genes

  --------------------------------------------------------------------------------------------------------------------------------------------------
  KEGG ID    KEGG term                     Count   *P*-value     Genes                                                              miRNA
  ---------- ----------------------------- ------- ------------- ------------------------------------------------------------------ ----------------
  hsa05200   Pathways in cancer            61      7.27×10^−5^   *GNA13, F2RL3, ADCY1, PPARD, FGF7, ADCY7, PTGS2, STAT5B,* etc      hsa-miR-508\
                                                                                                                                    hsa-miR-509-2\
                                                                                                                                    hsa-miR-526b

  hsa04010   MAPK signaling pathway        37      7.52×10^−3^   *FGF7, PPP3R1, PPM1A, PPP3R2, NFKB1, GNG12, TNFRSF1A, KRAS,* etc   hsa-miR-508\
                                                                                                                                    hsa-miR-509-2\
                                                                                                                                    hsa-miR-526b

  hsa04024   cAMP signaling pathway        29      1.68×10^−2^   *ADCY1, ADCY7, ATP1B4, OXTR, NFKB1, GRIN3B, GABBR2, CNGB1,* etc    hsa-miR-508\
                                                                                                                                    hsa-miR-509-2\
                                                                                                                                    hsa-miR-526b

  hsa04068   FoxO signaling pathway        21      2.35×10^−2^   *EGFR, IRS2, SGK1, RBL2, NLK, TGFBR1, SMAD4, SMAD3* etc.           hsa-miR-508\
                                                                                                                                    hsa-miR-509-2\
                                                                                                                                    hsa-miR-526b

  hsa04151   PI3K--Akt signaling pathway   44      2.94×10^−2^   *CSH2, FGF7, PHLPP2, TLR2, NFKB1, GNG12, IL7R, PTEN,* etc          hsa-miR-508\
                                                                                                                                    hsa-miR-509-2\
                                                                                                                                    hsa-miR-526b

  hsa04150   mTOR signaling pathway        11      4.07×10^−2^   *PRKCA, MAPK1, RPS6KA3, TSC1, IGF1, CAB39, RICTOR, PRKAA2,* etc    hsa-miR-508\
                                                                                                                                    hsa-miR-509-2\
                                                                                                                                    hsa-miR-526b
  --------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviation:** KEGG, Kyoto Encyclopedia of Genes and Genomes.
